Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Application of T-lymphocytes

Phase 2Small molecule

HHannover Medical School

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Progressive Multifocal Leucoencephalopathy (PML)Recruiting

Progressive Multifocal Leucoencephalopathy (PML)Phase 2

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Progressive Multifocal Leucoencephalopathy (PML)

NCT06990087

Clinical

Trials by Indication[1]

Progressive Multifocal Leucoencephalopathy (PML)1 trial

CurePML - Allogeneic HPyV-2-specific T-cell Therapy in Patients With Progressive Multifocal Leukoencephalopathy

Recruiting·HHannover Medical School·Phase 2·NCT06990087·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Application of T-lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Application of T-lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Application of T-lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hannover Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHannover Medical School

Related News